Imcyse SA

Imcyse SA is a clinical-stage biopharmaceutical company located in Liège, Belgium.

Founded in 2010 as a spin-off from the Catholic University of Leuven, Imcyse focuses on developing antigen-specific immunotherapies to treat severe chronic autoimmune diseases using its proprietary ImotopeTM technology platform. The company aims to transform the treatment landscape for these conditions by preventing, treating, and potentially curing diseases that are currently underserved by existing therapies. Imcyse's core technology involves administering specifically modified peptides, known as ImotopesTM, to generate cytolytic CD4 T-cells. These cells target and eliminate the immune cells responsible for damaging the affected organs, aiming to halt disease progression without compromising overall immune function. The company has a robust pipeline that includes clinical programs for Type 1 Diabetes and Multiple Sclerosis, as well as pre-clinical programs for conditions like Neuromyelitis Optica and Celiac Disease. Imcyse is committed to addressing the needs of patients suffering from severe autoimmune diseases where current treatments primarily manage symptoms.